<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02152969</url>
  </required_header>
  <id_info>
    <org_study_id>YH22162-101</org_study_id>
    <nct_id>NCT02152969</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)</brief_title>
  <official_title>An Open-label, Multiple-dose, Two-arm Clinical Study to Evaluate the Drug-drug Interaction and Safety of Telmisartan, Amlodipine and/or Chlorthalidone in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate Drug-drug interaction
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the Drug-Drug(telmisartan, amlodipine and/ or
      chlorthalidone) interaction and safety in healthy adult volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt ss, Cmax ss of telmisartan/amlodipine/chlorthalidone</measure>
    <time_frame>Totally 28points for 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmin ss, tmax ss, t1/2 of telmisartan/amlodipine/chlorthalidone</measure>
    <time_frame>Totally 28points for 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm to evaluate influence of Chlorthalidone on pharmacokinetics of amlodipine and telmisartan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm to evaluate influence of amlodipine and telmisartan on pharmacokinetics of Chlorthalidone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone</intervention_name>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant who has a body weight that is ≥55kg(male) or ≥50kg(female) with ideal body
             weight of 80-120% (ideal body weight)

          2. Who has not suffered from clinically significant disease

          3. Provision of signed written informed consent

        Exclusion Criteria:

          1. History of and clinically significant disease psychiatric, or malignancy.

          2. A history of drug abuse or the presence of positive reactions to drugs that have abuse
             potential in urine screenings for drugs.

          3. Administration of other investigational products within 3 months prior to the first
             dosing.

          4. Administration of herbal medicine within 2 weeks or administration of ethical drugs
             within 2 weeks or administration of over-the-counter (OTC) drugs within 1 week prior
             to the first dosing of the investigational product (if the investigator (study doctor)
             determines that the person meets other criteria appropriately, the relevant person may
             participate in the study).

          5. Volunteers considered not eligible for the clinical trial by the investigator (study
             doctor) due to reasons including laboratory test results, ECGs, or vital signs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Seok Yim</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2014</study_first_submitted>
  <study_first_submitted_qc>May 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <last_update_submitted>November 18, 2014</last_update_submitted>
  <last_update_submitted_qc>November 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

